350 Afleveringen

  1. 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

    Gepubliceerd: 27-7-2023
  2. 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

    Gepubliceerd: 20-7-2023
  3. 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

    Gepubliceerd: 13-7-2023
  4. 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

    Gepubliceerd: 29-6-2023
  5. 264: Messy PBM conflicts, debatable vaccines, & the future of flu season

    Gepubliceerd: 22-6-2023
  6. 263: Biogen's messy board, Laronde's data problem, & the downside of a boom

    Gepubliceerd: 15-6-2023
  7. 262: Merck v. USA, the best of ASCO, and Leqembi at the FDA

    Gepubliceerd: 8-6-2023
  8. 261: Fake medical devices, real cancer drugs, & curious Ozempic effects

    Gepubliceerd: 1-6-2023
  9. 260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

    Gepubliceerd: 25-5-2023
  10. 259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

    Gepubliceerd: 18-5-2023
  11. 258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

    Gepubliceerd: 11-5-2023
  12. 257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

    Gepubliceerd: 4-5-2023
  13. 256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

    Gepubliceerd: 27-4-2023
  14. 255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters

    Gepubliceerd: 20-4-2023
  15. 254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

    Gepubliceerd: 13-4-2023
  16. 253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

    Gepubliceerd: 6-4-2023
  17. 252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

    Gepubliceerd: 30-3-2023
  18. 251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster

    Gepubliceerd: 23-3-2023
  19. 250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

    Gepubliceerd: 16-3-2023
  20. 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

    Gepubliceerd: 9-3-2023

5 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site